5395232026-04-012026-06-305395232026-06-305395232026-04-012026-06-30in-capmkt:OtherExpenses1Member5395232026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-142026-07-21INRMillionsQuarterlyFirst quarterSingle segmentThe Company is exclusively engaged in pharmaceutical business2026-08-1411:00:002026-08-1413:40:00Not applicablefalsetrue2026-04-012026-06-30UnauditedStandalone2667730000013662000002804350000067288000001466600000-6349000005474700000175200000572200000627670000020059300000798420000007984200000207740000020700000022844000000569980000000005699800000-256000005674200000239100000247.6747.670047.6747.670001) The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <br /> <br /> 2) The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 13 August 2026 and subsequently approved by the Board of Directors at its meeting held on 14 August 2026. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2026. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. <br /> <br /> 3) The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited. <br /> During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". <br /> <br /> Key financial information of Discontinued Operations: <br /> <br /> Particulars: <br /> <br /> Quarter ended June 30, 2026: <br /> <br /> Total income: NIL <br /> Total expenses: NIL <br /> Profit before tax: NIL <br /> Total tax expense: NIL <br /> Net profit for the period after tax: NIL <br /> <br /> Quarter ended March 31, 2026 <br /> <br /> Total income: NIL <br /> Total expenses: NIL <br /> Profit before tax: NIL <br /> Total tax expense: NIL <br /> Net profit for the period after tax: NIL <br /> <br /> YTD June 30, 2025 <br /> <br /> Total income: 3,558.2 <br /> Total expenses: 3,037.2 <br /> Profit before tax: 521.0 <br /> Total tax expense: 182.0 <br /> Net profit for the period after tax: 339.0 <br /> <br /> Year end March 31, 2026 <br /> <br /> Total income: 9,181.0 <br /> Total expenses: 7,690.5 <br /> Profit before tax: 1,490.5 <br /> Total tax expense: 520.8 <br /> Net profit for the period after tax: 969.7 <br /> <br /> 4) Exceptional items include: <br /> <br /> 1) During the quarter and year ended 31 March 2026 year, the Company reviewed its investments in real estate; where recoverability was subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to Rs. 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026. <br /> <br /> 2) During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. <br /> Based on this assessment, the Company recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs. 445.1 million in the quarter ended 31 March 2026 and of Rs. 826.8 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. <br /> <br /> 3) The Company sold its Indore manufacturing facility in the quarter ended 30 June 2025. The resulting gain (arising out of reversal of impairment loss) amounting to Rs.142.9 million had been classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2025 and year ended 31 March 2026. <br /> <br /> 5) During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company has decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate as at 31 March 2026. Subsequently in the current quarter tax expense has been recognized based on the enacted tax rates applicable under the new regime. <br /> <br /> 6) The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made. <br /> Other Expenses6276700000tems that will not be reclassified to profit or loss-34200000-34200000-86000000-2560000000000